EverHint Signal — EMA10 × EMA30 Crossover (Top 15 ranked by RSI) — January 06, 2026
What This Signal Is (Quick)
The EMA10 × EMA30 crossover is a momentum strategy that catches short-term trend shifts. When the 10-day exponential moving average crosses above the 30-day EMA, that's a buy signal—indicating accelerating upward momentum. When it crosses below, that's a sell signal—suggesting weakening momentum or potential reversal.
This is a faster, more responsive setup than longer-term crossovers like EMA10 × SMA50. You'll see more signals, which means more opportunities, but also more whipsaw risk in choppy markets. It's ideal for swing traders looking to capture 1-4 week moves.
This is an experimental scanner. These signals are for educational purposes and backtesting—not trade recommendations. Always do your own due diligence.
How We Ranked Today (Reader Version)
We ranked buy signals by RSI(14), with lower RSI values ranked higher. Why? Lower RSI often indicates oversold conditions, which can mean better risk/reward entries when paired with a fresh bullish crossover.
We've also overlaid:
- Insider Net (USD): Net insider buying or selling over the last 90 days (purchases minus sales only—awards and exercises excluded)
- Days → Earnings: How many days until the next earnings report (useful for managing event risk)
- Analyst coverage and recent news where relevant
These signals are designed to help you spot potential setups and understand the context—not to tell you what to buy or sell.
📈 Buy-Side Signals
We scanned 66 buy signals today. Here are the top 15 ranked by RSI (lowest to highest):
| Rank | Ticker | Company | Sector | Last ($) | RSI(14) | Days → Earnings |
|---|---|---|---|---|---|---|
| 1 | ABCB | Ameris Bancorp | Financial Services | 76.20 | 34.96 | 23 |
| 2 | INGR | Ingredion Incorporated | Consumer Defensive | 111.34 | 40.67 | 28 |
| 3 | PK | Park Hotels & Resorts Inc. | Real Estate | 10.83 | 45.87 | 43 |
| 4 | POR | Portland General Electric Company | Utilities | 48.72 | 44.51 | 38 |
| 5 | ABEV | Ambev S.A. | Consumer Defensive | 2.51 | 46.72 | 50 |
| 6 | PAGS | PagSeguro Digital Ltd. | Technology | 9.90 | 47.12 | 45 |
| 7 | LPX | Louisiana-Pacific Corporation | Industrials | 85.11 | 47.89 | 43 |
| 8 | AUB | Atlantic Union Bankshares Corporation | Financial Services | 36.91 | 50.71 | 16 |
| 9 | TS | Tenaris S.A. | Energy | 40.36 | 50.30 | 43 |
| 10 | MCK | McKesson Corporation | Healthcare | 826.51 | 52.78 | 29 |
| 11 | CPA | Copa Holdings, S.A. | Industrials | 127.31 | 53.28 | 36 |
| 12 | OC | Owens Corning | Industrials | 116.21 | 53.83 | 48 |
| 13 | TTEK | Tetra Tech, Inc. | Industrials | 34.77 | 54.95 | 29 |
| 14 | OWL | Blue Owl Capital Inc. | Financial Services | 16.04 | 55.99 | 30 |
| 15 | HCA | HCA Healthcare, Inc. | Healthcare | 483.60 | 56.32 | 17 |
Field Notes:
- ABCB (Ameris Bancorp) leads with RSI at 34.96—deeply oversold for a regional bank. Earnings in 23 days. No significant insider activity.
- INGR (Ingredion) at RSI 40.67 shows value in consumer staples. Insiders have been neutral.
- PK (Park Hotels & Resorts) trades at $10.83 with RSI 45.87—a potential real estate play as lodging demand stabilizes.
- HCA Healthcare at $483.60 is a mega-cap healthcare name with earnings just 17 days out—watch for pre-earnings volatility.
- MCK (McKesson) is a high-conviction pick at $826.51, RSI 52.78, with strong fundamentals in pharmaceutical distribution.
Strong Momentum Names (RSI > 70):
Several names flashed crossovers with RSI already above 70, indicating strong momentum but overbought conditions:
- NICE Ltd. (RSI 89.20) at $117.74—AI-powered software surging
- OGN (Organon) (RSI 82.35) at $8.07—pharma value play
- OS (OneStream) (RSI 82.53) at $23.61—just announced $6.4B buyout by Hg Capital
- AVTR (Avantor) (RSI 81.39) at $12.27—life sciences supplier with insider buying ($993K purchase by CEO)
- TECH (Bio-Techne) (RSI 79.96) at $65.28—biotech tools gaining traction
Recent Headlines (Buy Signals):
- AEVA: Nvidia partnership announced—Aeva's 4D LiDAR selected for NVIDIA DRIVE Hyperion platform. Stock surged 35% on the news. Insider selling noted ($8.3M in sales by executives).
- OS (OneStream): Going private in $6.4B Hg Capital deal at $24/share (31% premium). Stock jumped on buyout news.
- AVTR (Avantor): CEO Emmanuel Ligner purchased $993K in shares (87,500 shares at $11.35)—bullish insider signal.
- APLD (Applied Digital): AI infrastructure momentum building with $16B in long-term leases. Earnings Jan 13.
- ETSY: Rebounding from oversold levels; insider selling noted ($329K by CAO).
📉 Sell-Side Signals
We scanned 29 sell signals today. Here are the top 10 ranked by RSI (highest to lowest):
| Rank | Ticker | Company | Sector | Last ($) | RSI(14) | Days → Earnings |
|---|---|---|---|---|---|---|
| 1 | CRK | Comstock Resources, Inc. | Energy | 22.90 | 57.48 | 42 |
| 2 | PVLA | Palvella Therapeutics, Inc. | Healthcare | 90.43 | 51.37 | 83 |
| 3 | CEG | Constellation Energy Corporation | Utilities | 354.58 | 48.74 | 42 |
| 4 | RCUS | Arcus Biosciences, Inc. | Healthcare | 21.69 | 48.15 | 49 |
| 5 | BJ | BJ's Wholesale Club Holdings, Inc. | Consumer Defensive | 90.88 | 48.34 | 58 |
| 6 | ESS | Essex Property Trust, Inc. | Real Estate | 256.61 | 46.52 | 28 |
| 7 | CME | CME Group Inc. | Financial Services | 269.15 | 46.34 | 36 |
| 8 | CNQ | Canadian Natural Resources Limited | Energy | 31.59 | 44.93 | 58 |
| 9 | ABBV | AbbVie Inc. | Healthcare | 223.93 | 44.03 | 24 |
| 10 | QTWO | Q2 Holdings, Inc. | Technology | 70.29 | 39.02 | 36 |
Field Notes:
- CRK (Comstock Resources) at RSI 57.48 shows relative strength even as the crossover turns bearish—energy sector headwinds with crude oil down 2.3%.
- ABBV (AbbVie) at $223.93 flashes a sell signal with RSI 44.03. Healthcare giant facing near-term headwinds despite strong dividend profile. Earnings in 24 days.
- CEG (Constellation Energy) at $354.58 (RSI 48.74) sees momentum cooling after a strong 2025 run in utilities.
- BJ (BJ's Wholesale Club) at $90.88 showing distribution—insider gifting noted (24,972 shares by EVP).
Recent Headlines (Sell Signals):
- OWL (Blue Owl Capital): Multiple securities fraud lawsuits filed; class action for investors Feb 6-Nov 16, 2025. Stock under legal pressure.
- ABBV (AbbVie): "Rocky near-term, positive long-term" outlook per analysts. Elevated P/E and MFN-driven profit pressure noted.
- FLEX (Flex Ltd.): Insider selling continues ($719K by CAO, $580K by director).
- PTGX (Protagonist Therapeutics): RSI 16.66—deeply oversold biotech with sell signal. High volatility expected.
Field Notes
Key Metrics Explained:
- RSI(14): Relative Strength Index on a 0-100 scale. Below 30 = oversold, above 70 = overbought. We rank buy signals by lowest RSI (better value entry).
- Insider Net (USD): Net insider purchases minus sales over 90 days. Positive = bullish, negative = bearish. Excludes awards/exercises.
- Days → Earnings: Time until next earnings report. <7 days = high volatility risk, 7-30 days = moderate risk, >30 days = lower event risk.
Sector Rotation Observations:
- Industrials dominate buy signals (12 names): AGCO, AXON, BLD, BWXT, CPA, FSS, JOBY, OC, OTIS, SERV, SYM, TTEK, ULS, WCC, WSC. Construction, aerospace, and manufacturing momentum building.
- Healthcare mixed: 11 buy signals vs. 5 sell signals. Value opportunities in AVTR, OGN, BIO, GRAL, but mega-caps like ABBV showing weakness.
- Technology: 9 buy signals including AEVA (Nvidia deal), OS (buyout), NICE (AI momentum), PONY (autonomy).
- Energy consolidation: 2 buys (LEU at $311.89, VLO at $178.27) vs. 5 sells (CNQ, CRK, PR, MPLX, VIST). Crude oil down 2.3% pressuring sector.
RSI Interpretation:
- Deep value zone (RSI < 40): ABCB, INGR, PTGX (sell signal). These are contrarian plays with higher risk but potentially better reward if momentum reverses.
- Sweet spot (RSI 40-60): AUB, PAGS, LPX, HCA, MCK. Balanced momentum with crossover confirmation.
- Momentum zone (RSI > 70): NICE, OGN, OS, AVTR, TECH. Strong trends but overbought—consider waiting for pullbacks or use tight stops.
Vlad's Take (EverHint)
Market Backdrop (Jan 6, 2026):
Markets extended gains Tuesday with the S&P 500 up 0.53% to 6,944.83 (new all-time high), Nasdaq up 0.43% to 23,547.17, and Dow up 0.97% to 49,462.09. The VIX closed at 14.75 (down 1.67%), indicating low-to-normal volatility but still above complacency levels. Small-caps outperformed with Russell 2000 up 1.49% to 2,582.90—a bullish breadth signal. Treasury yields ticked higher (10Y at 4.179%, up 0.14%), applying slight pressure to growth stocks. Crude oil fell 2.3% to $57.00, pressuring energy names. Bitcoin dipped 0.39% to $93,497, while Ethereum gained 1.84% to $3,284. Overall: risk-on environment with broad market strength, but rising yields and energy weakness bear watching.
Strategy Commentary:
With 66 buy signals and 29 sell signals, the EMA10 × EMA30 crossover is flashing net bullish—but quality matters more than quantity here. Given the elevated market (S&P at all-time highs) and rising yields, I'd focus on:
- Industrials with momentum (AXON, BWXT, BLD)—infrastructure and defense tailwinds intact.
- Deep value healthcare (AVTR with insider buying, OGN at $8)—beaten-down names with crossover confirmation.
- Avoid energy sells—crude oil weakness could persist near-term.
Trading Tips:
- Tiered entries: Don't chase the RSI > 80 names (NICE, OGN, OS). Wait for 5-10% pullbacks or skip them entirely.
- Use stops: VIX at 14.75 isn't panic, but it's not complacent either. Keep stops tight (5-8% below entry).
- Earnings risk: HCA (17 days), ABCB (23 days), ABBV (24 days) all have earnings within a month. Consider half-size positions or wait until after earnings.
- Insider buying = green light: AVTR (CEO bought $993K) is a strong signal. Follow the smart money.
How Market Conditions Affect Signal Quality:
In risk-on environments like today, bullish crossovers tend to follow through better. But with small-cap outperformance (Russell +1.49%), we could be seeing late-cycle rotation. Don't overstay your welcome—take profits on 10-15% gains and trail stops aggressively.
💡 If this analysis helped you, feel free to like, share, or subscribe — it helps the channel grow steadily.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/